NASDAQ:KRRO Korro Bio (KRRO) Stock Price, News & Analysis $20.07 +0.03 (+0.15%) Closing price 08/25/2025 04:00 PM EasternExtended Trading$20.62 +0.55 (+2.74%) As of 08/25/2025 07:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Korro Bio Stock (NASDAQ:KRRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Korro Bio alerts:Sign Up Key Stats Today's Range$19.54▼$21.3650-Day Range$11.75▼$20.5552-Week Range$10.29▼$98.00Volume57,033 shsAverage Volume132,285 shsMarket Capitalization$188.46 millionP/E RatioN/ADividend YieldN/APrice Target$86.83Consensus RatingBuy Company Overview Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts. Read More Korro Bio Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScoreKRRO MarketRank™: Korro Bio scored higher than 26% of companies evaluated by MarketBeat, and ranked 823rd out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingKorro Bio has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKorro Bio has only been the subject of 3 research reports in the past 90 days.Read more about Korro Bio's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Korro Bio are expected to decrease in the coming year, from ($9.52) to ($10.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Korro Bio is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Korro Bio is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKorro Bio has a P/B Ratio of 1.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Korro Bio's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted21.68% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Korro Bio has recently increased by 8.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKorro Bio does not currently pay a dividend.Dividend GrowthKorro Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted21.68% of the float of Korro Bio has been sold short.Short Interest Ratio / Days to CoverKorro Bio has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in Korro Bio has recently increased by 8.18%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.24 News SentimentKorro Bio has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Korro Bio this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for KRRO on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Korro Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of Korro Bio is held by insiders.Percentage Held by InstitutionsOnly 13.18% of the stock of Korro Bio is held by institutions.Read more about Korro Bio's insider trading history. Receive KRRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Korro Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address KRRO Stock News HeadlinesHead to Head Analysis: Korro Bio (NASDAQ:KRRO) vs. Ainos (NASDAQ:AIMD)August 20, 2025 | americanbankingnews.comKorro Bio, Inc. (NASDAQ:KRRO) Receives $86.83 Consensus Target Price from BrokeragesAugust 20, 2025 | americanbankingnews.comTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed professionals, retirees, and high-net-worth savers. But the wealthy aren’t just writing checks. They’re moving fast to protect capital and purchasing power using legal, IRS-compliant strategies. American Alternative Assets just released the Mar-A-Lago Accord, a free guide revealing how to reduce Q3 tax exposure and reposition wealth before it’s drained. | American Alternative (Ad)HC Wainwright Has Negative Outlook for Korro Bio Q3 EarningsAugust 17, 2025 | americanbankingnews.comWilliam Blair Issues Positive Outlook for Korro Bio EarningsAugust 16, 2025 | americanbankingnews.comKorro Bio (NASDAQ:KRRO) Price Target Lowered to $147.00 at Raymond James FinancialAugust 15, 2025 | americanbankingnews.comKorro Bio price target lowered to $90 from $100 at H.C. WainwrightAugust 13, 2025 | msn.comKorro Bio Advances RNA Editing Programs in Q2 2025August 13, 2025 | msn.comSee More Headlines KRRO Stock Analysis - Frequently Asked Questions How have KRRO shares performed this year? Korro Bio's stock was trading at $38.07 on January 1st, 2025. Since then, KRRO shares have decreased by 47.3% and is now trading at $20.07. How were Korro Bio's earnings last quarter? Korro Bio, Inc. (NASDAQ:KRRO) posted its earnings results on Tuesday, August, 12th. The company reported ($2.74) EPS for the quarter, missing the consensus estimate of ($2.54) by $0.20. The company had revenue of $1.46 million for the quarter, compared to analyst estimates of $0.41 million. Who are Korro Bio's major shareholders? Top institutional investors of Korro Bio include Geode Capital Management LLC (1.65%), Raymond James Financial Inc. (0.89%), Bank of America Corp DE (0.30%) and AlphaQuest LLC (0.29%). Insiders that own company stock include Venture Opportunity Fund Atlas, David L Lucchino and Vineet Agarwal. View institutional ownership trends. How do I buy shares of Korro Bio? Shares of KRRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Korro Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Korro Bio investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Home Depot (HD). Company Calendar Last Earnings8/12/2025Today8/26/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KRRO Previous SymbolNASDAQ:KRRO CIK1703647 Webwww.frequencytx.com Phone781-315-4600FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Price Target for Korro Bio$86.83 High Price Target$147.00 Low Price Target$25.00 Potential Upside/Downside+332.7%Consensus RatingBuy Rating Score (0-4)3.29 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($9.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$83.58 million Net MarginsN/A Pretax Margin-1,452.95% Return on Equity-61.51% Return on Assets-42.87% Debt Debt-to-Equity RatioN/A Current Ratio5.98 Quick Ratio5.98 Sales & Book Value Annual Sales$2.27 million Price / Sales83.02 Cash FlowN/A Price / Cash FlowN/A Book Value$17.12 per share Price / Book1.17Miscellaneous Outstanding Shares9,390,000Free Float8,959,000Market Cap$188.46 million OptionableNo Data Beta2.51 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:KRRO) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 17th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.